TIRZEPATIDE

Weight Loss & MetabolicPrescription Available

Exceptional clinical trial results with FDA approval backing its efficacy profile. Among the strongest evidence bases in the weight loss peptide category.

Primarily studied by endocrinologists and obesity researchers investigating next-generation diabetes and weight management therapeutics.

FDA Status

FDA Approved

Since Nov 2023

Evidence

Strong

Studies

30 total, 1 human

Popularity

#2 most researched

What is TIRZEPATIDE?

Originally developed by Eli Lilly as Mounjaro for diabetes treatment, this dual-receptor peptide has become one of the most studied weight loss compounds in recent years. Clinical trials have demonstrated weight loss results that often exceed those seen with single-receptor agonists like semaglutide. Research interest has intensified following FDA restrictions on compounded versions, making it a priority target for metabolic researchers.

The peptide simultaneously activates two key hormone receptors in the gut: GLP-1, which slows gastric emptying and reduces appetite, and GIP, which enhances insulin sensitivity and may influence fat metabolism. Think of it as hitting two metabolic switches at once rather than just one, which appears to create a more comprehensive effect on blood sugar control and satiety signals than peptides that target only a single pathway.

What the Research Shows

Strong human trial data including large-scale Phase 3 studies, though the research literature outside of pharmaceutical-sponsored trials remains limited.